Suchergebnisse - (Standardsuche:ritonavir)

PubPharm (8.747)

1

Drug resistance patterns in HIV patients with virologic failure in Iran

enthalten in: Archives of clinical infectious diseases | 2019

von Alinaghi, S. | Rasoolinejad, M. | Najafi, Z. | +3

2

Dual therapy with ritonavir-boosted protease inhibitor (PI) plus lamivudine versus triple therapy with ritonavir-boosted PI plus two nucleos(t)ide reverse-transcriptase inhibitor in HIV-infected patients with viral suppression

enthalten in: Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi | 2019

von Hung, T. | Chen, G. | Cheng, S. | +4

3

Amorphous solid dispersion formation via solvent granulation - A case study with ritonavir and lopinavir

enthalten in: International journal of pharmaceutics: X | 2019

von Trasi, N. | Bhujbal, S. | Zhou, Q. | +1

4

A First-in-Human Trial of GLS4, a Novel Inhibitor of Hepatitis B Virus Capsid Assembly, following Single- and Multiple-Ascending-Oral-Dose Studies with or without Ritonavir in Healthy Adult Volunteers

enthalten in: Antimicrobial agents and chemotherapy | 2019

von Zhao, N. | Jia, B. | Zhao, H. | +9

5

Response to direct-acting antiviral agents in chronic hepatitis C patients with end-stage renal disease : a clinical experience

enthalten in: Revista da Associacao Medica Brasileira (1992) | 2019

von Tatar, B. | Köse, �. | Ergun, N. | +4

CommentIn: Rev Assoc Med Bras (1992). 2021 Jun;67(6):909. - PMID 34709345

6

Efficacy and safety of the new antiviral agents for the treatment of hepatitis C virus infection in Egyptian renal transplant recipients

enthalten in: International urology and nephrology | 2019

von Maghrabi, H. | Elmowafy, A. | Refaie, A. | +4

7

Reduction of Immune Activation and Partial Recovery of Staphylococcal Enterotoxin B-Induced Cytokine Production After Switching to an Integrase Strand Transfer Inhibitor-Containing Regimen : Results from an Observational Cohort Study

enthalten in: Clinical drug investigation | 2019

von Merlini, E. | Cazzaniga, F. | Casabianca, A. | +6

8

Switch to MK-1439A (once a day) from a Ritonavir-boosted Protease Inhibitor regimen in HIV-1 infected subjects : A Phase III Multicenter, Open-Label, Randomized Study to Evaluate a Switch to MK-1439A in HIV-1-Infected Subjects Virologically Suppressed on a Regimen of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs). SUBTITLE: Amendment to Include Switches From Additional Antiretroviral Regimens - Switch to MK-1439A from PI, EVG- or NNRTI-based regimen for HIV-1 infection

enthalten in: WHO International Clinical Trials Registry Platform | 2019

9

Annovera - a new contraceptive vaginal ring

enthalten in: The Medical letter on drugs and therapeutics | 2019

10

Switch to MK-1439A (once a day) from a Ritonavir-boosted Protease Inhibitor regimen in HIV-1 infected subjects : A Phase III Multicenter, Open-Label, Randomized Study to Evaluate a Switch to MK-1439A in HIV-1-Infected Subjects Virologically Suppressed on a Regimen of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs). SUBTITLE: Amendment to Include Switches From Additional Antiretroviral Regimens - Switch to MK-1439A from PI, EVG- or NNRTI-based regimen for HIV-1 infection

enthalten in: WHO International Clinical Trials Registry Platform | 2019

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[875]